Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Frederick, Barkhof"'
Autor:
Jonathan Bennett, Maud van Dinther, Paulien Voorter, Walter Backes, Josephine Barnes, Frederick Barkhof, Gabriella Captur, Alun D. Hughes, Carole Sudre, Thomas A. Treibel
Publikováno v:
Medicina, Vol 59, Iss 9, p 1596 (2023)
The objective of this review is to investigate the commonalities of microvascular (small vessel) disease in heart failure with preserved ejection fraction (HFpEF) and cerebral small vessel disease (CSVD). Furthermore, the review aims to evaluate the
Externí odkaz:
https://doaj.org/article/7f210689711649d4975f76bff8f34e3d
Autor:
Chris, Polman, Ludwig, Kappos, Mark S, Freedman, Gilles, Edan, Hans-Peter, Hartung, David H, Miller, Xavier, Montalbán, Frederick, Barkhof, Krzysztof, Selmaj, Bernard M J, Uitdehaag, Susanne, Dahms, Lars, Bauer, Christoph, Pohl, Rupert, Sandbrink, S, Howell
Publikováno v:
Journal of neurology, Vol. 255, no.4, p. 480-7 (2008)
Journal of Neurology, 255(4), 480-487. D. Steinkopff-Verlag
Polman, C, Kappos, L, Freedman, M, Edan, G, Hartung, H P, Miller, D H, Montalbán, X, Barkhof, F, Selmaj, K, Uitdehaag, B, Dahms, S, Bauer, L, Pohl, C & Sandbrink, R 2007, ' Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b ', Journal of Neurology .
Journal of Neurology. D. Steinkopff-Verlag
Polman, C H, Kappos, L, Freedman, M S, Edan, G, Hartung, H P, Miller, D H, Montalban, X, Barkhof, F, Selmaj, K, Uitdehaag, B M J, Dahms, S, Bauer, L, Pohl, C & Sandbrink, R 2008, ' Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b ', Journal of Neurology, vol. 255, no. 4, pp. 480-487 . https://doi.org/10.1007/s00415-007-0733-2
Journal of Neurology, 255(4), 480-487. D. Steinkopff-Verlag
Polman, C, Kappos, L, Freedman, M, Edan, G, Hartung, H P, Miller, D H, Montalbán, X, Barkhof, F, Selmaj, K, Uitdehaag, B, Dahms, S, Bauer, L, Pohl, C & Sandbrink, R 2007, ' Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b ', Journal of Neurology .
Journal of Neurology. D. Steinkopff-Verlag
Polman, C H, Kappos, L, Freedman, M S, Edan, G, Hartung, H P, Miller, D H, Montalban, X, Barkhof, F, Selmaj, K, Uitdehaag, B M J, Dahms, S, Bauer, L, Pohl, C & Sandbrink, R 2008, ' Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b ', Journal of Neurology, vol. 255, no. 4, pp. 480-487 . https://doi.org/10.1007/s00415-007-0733-2
BACKGROUND : The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and > or = 2 clinically silent brain MRI lesions. METHODS : Subgroups of 468 patients (IFNB-1b: n = 292; placebo: n = 176)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e80cda843df17a9d368fc9d69af95b42
https://pubmed.ncbi.nlm.nih.gov/18004635
https://pubmed.ncbi.nlm.nih.gov/18004635
Autor:
Daniel R. Altmann, Derek Soon, Frederick Barkhof, Bruce Gray, K Fernando, Paul O'Connor, Garin Giovannoni, Chris H. Polman, Michael Panzara, David Miller
Publikováno v:
Journal of neurology. 254(3)
Natalizumab, an anti-alpha4 integrin antibody, significantly reduces the number of visibly enhancing multiple sclerosis (MS) lesions. In this substudy of a 2-year trial of natalizumab monotherapy versus placebo, contrast-enhanced imaging investigated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8d134faac1c5f90d6647d3e38c686ec
https://pubmed.ncbi.nlm.nih.gov/17277910
https://pubmed.ncbi.nlm.nih.gov/17277910